KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Acquisitions (2018 - 2021)

Amneal Pharmaceuticals has reported Acquisitions over the past 3 years, most recently at $72.7 million for Q4 2021.

For Q4 2021, Acquisitions changed N/A year-over-year to $72.7 million; the TTM value through Dec 2022 reached $72.7 million, down 50.38%, while the annual FY2022 figure was $84.7 million, 42.19% down from the prior year.
Acquisitions for Q4 2021 was $72.7 million at Amneal Pharmaceuticals, down from $73.8 million in the prior quarter.
Over five years, Acquisitions peaked at $253.6 million in Q1 2020 and troughed at -$2.6 million in Q3 2020.
A 3-year average of $66.9 million and a median of $38.0 million in 2018 define the central range for Acquisitions.
On a YoY basis, Acquisitions climbed as much as 19587.47% in 2021 and fell as far as 19587.47% in 2021.
Year by year, Acquisitions stood at $3.3 million in 2018, then tumbled by 179.76% to -$2.6 million in 2020, then skyrocketed by 2854.36% to $72.7 million in 2021.
Business Quant data shows Acquisitions for AMRX at $72.7 million in Q4 2021, $73.8 million in Q2 2021, and -$2.6 million in Q3 2020.